A 68-Year-Old Woman With Stage IV Ovarian Cancer - Episode 7
Ramez Eskander, MD: This is a very exciting time for us in the treatment of patients with advanced-stage ovarian cancer. We have made significant gains over the last several years with the approval of olaparib in the frontline setting following the SOLO-1 trial, with incorporation of bevacizumab as a maintenance opportunity for patients with advanced-stage disease, and now, with a better understanding about these molecular predictors of potential response to therapy.
Not long ago, BRCA assessment, both in germline, and more important recently, somatic assessments, were not germane to the care of our patients. But this has transformed the paradigm of treatment in patients with advanced-stage ovarian cancer. I anticipate that this paradigm will continue to evolve over the coming years. Certainly the data that emerge from the various front-line combination trials, the ATHENA and FIRST trials, looking at combinations of immuno-oncology plus PARP inhibitor, or antiangiogenic therapy plus immune checkpoint inhibitors, IMagyn050 trial, all of which are going to help inform the path forward, and hopefully, with incorporation of translational end points on these studies, guide our design of future trials.
Transcript edited for clarity.